Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Global mRNA Vaccines & Therapeutics main manufactuers include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology, etc. Europe is the largest market of mRNA vaccines and therapeutics, with a share more than 10%. As for the types of products, it can be divided into infectious disease vaccines and cancer vaccines, which account for about 85%, 15% respectively. In terms of applications, it is widely used in infectious disease and caner, taking proportions 85%, 15% respectively.
The global mRNA Vaccines & Therapeutics market was valued at US$ million in 2020 and is expected to reach US$ 228730 million by the end of 2027, growing at a CAGR of 35.7% during 2021-2027.
This report focuses on mRNA Vaccines & Therapeutics volume and value at the global level, regional level and company level. From a global perspective, this report represents overall mRNA Vaccines & Therapeutics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global mRNA Vaccines & Therapeutics Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
Segment by Application
Infectious Disease
Cancer
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Global mRNA Vaccines & Therapeutics main manufactuers include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology, etc. Europe is the largest market of mRNA vaccines and therapeutics, with a share more than 10%. As for the types of products, it can be divided into infectious disease vaccines and cancer vaccines, which account for about 85%, 15% respectively. In terms of applications, it is widely used in infectious disease and caner, taking proportions 85%, 15% respectively.
The global mRNA Vaccines & Therapeutics market was valued at US$ million in 2020 and is expected to reach US$ 228730 million by the end of 2027, growing at a CAGR of 35.7% during 2021-2027.
This report focuses on mRNA Vaccines & Therapeutics volume and value at the global level, regional level and company level. From a global perspective, this report represents overall mRNA Vaccines & Therapeutics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global mRNA Vaccines & Therapeutics Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
Segment by Application
Infectious Disease
Cancer
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
